By Connor Hart
Jacobs Solutions disclosed post-closing adjustments stemming from a transaction it completed with Amentum last year. The Dallas company received $70 million and the right to receive nearly 7.3 million shares of Amentum's common stock. Jacobs used the money to repay a portion of debt and plans to distribute Amentum's stock to its shareholders. Shares up 6.9%, to $122.80, in after-hours trading.
Argenx received approval from the Food and Drug Administration for a new delivery method of its treatment for certain patients with a rare autoimmune disease. The approval of the treatment, Vyvgart Hytrulo, in a prefilled syringe for self-injection is supported by data from studies evaluating its bioequivalence to the treatment in a vial, the immunology company said. The prefilled syringe is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver or healthcare professional. American depositary receipts rise 6.2%, to $580, in post-market trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 10, 2025 19:29 ET (23:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.